|                 |                     |                        | p-value for        |
|-----------------|---------------------|------------------------|--------------------|
|                 | Pilot Trial<br>n=20 | Phase II trial<br>n=41 | difference between |
|                 |                     |                        | two study groups   |
| Overall         | 15/20 (75%)         | 27/41 (66%)            | 0.34               |
| Skin            | 10/14 (71%)         | 19/23 (83%)            | 0.10               |
| Liver           | 1/4 (25%)           | 5/5 (100%)             | 0.06               |
| GI              | 8/11 (73%)          | 18/26 (69%)            | 0.84               |
| Grade II        | 13/14 (93%)         | 19/27 (67%)            | 0.10               |
| Grade III-IV    | 2/6 (33%)           | 8/14 (57%)             | 0.34               |
| Related Donor   | 12/14 (86%)         | 20/28 (71%)            | 0.31               |
| Unrelated Donor | 3/6 (50%)           | 7/13 (54%)             | 0.88               |